$179.84
Zoetis Inc is a global animal health company that produces and markets vaccines, medicines, and diagnostics for pets and livestock.
0.31%
Downside
Day's Volatility :2.23%
Upside
1.92%
19.67%
Downside
52 Weeks Volatility :27.92%
Upside
10.26%
Period | Zoetis Inc. | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | 14.1% | 6.5% | 5.9% |
6 Months | -5.62% | 7.1% | 10.4% |
1 Year | -5.85% | 9.8% | 18.2% |
3 Years | -9.99% | 14.2% | 22.1% |
Market Capitalization | 82.0B |
Book Value | $11.07 |
Dividend Share | 1.557 |
Dividend Yield | 0.96% |
Earnings Per Share (EPS) | 5.19 |
PE Ratio | 34.62 |
PEG Ratio | 2.58 |
Wall Street Target Price | 214.36 |
Profit Margin | 27.38% |
Operating Margin TTM | 36.58% |
Return On Assets TTM | 13.99% |
Return On Equity TTM | 50.05% |
Revenue TTM | 8.7B |
Revenue Per Share TTM | 19.0 |
Quarterly Revenue Growth YOY | 9.5% |
Gross Profit TTM | 5.6B |
EBITDA | 3.6B |
Diluted Eps TTM | 5.19 |
Quarterly Earnings Growth YOY | 0.1 |
EPS Estimate Current Year | 5.77 |
EPS Estimate Next Year | 6.39 |
EPS Estimate Current Quarter | 1.34 |
EPS Estimate Next Quarter | 1.51 |
What analysts predicted
Upside of 19.19%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 5.8B | ↑ 9.76% |
Net Income | 1.4B | ↑ 65.28% |
Net Profit Margin | 24.52% | ↑ 8.24% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 6.3B | ↑ 7.47% |
Net Income | 1.5B | ↑ 5.04% |
Net Profit Margin | 23.96% | ↓ 0.56% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 6.7B | ↑ 6.63% |
Net Income | 1.6B | ↑ 9.2% |
Net Profit Margin | 24.54% | ↑ 0.58% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 7.8B | ↑ 16.49% |
Net Income | 2.0B | ↑ 24.36% |
Net Profit Margin | 26.2% | ↑ 1.66% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 8.1B | ↑ 3.91% |
Net Income | 2.1B | ↑ 3.78% |
Net Profit Margin | 26.16% | ↓ 0.04% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 8.5B | ↑ 5.74% |
Net Income | 2.3B | ↑ 10.88% |
Net Profit Margin | 27.43% | ↑ 1.27% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 2.0B | ↑ 1.9% |
Net Income | 461.0M | ↓ 12.85% |
Net Profit Margin | 22.6% | ↓ 3.82% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.0B | ↓ 1.96% |
Net Income | 552.0M | ↑ 19.74% |
Net Profit Margin | 27.6% | ↑ 5.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.2B | ↑ 9.0% |
Net Income | 671.0M | ↑ 21.56% |
Net Profit Margin | 30.78% | ↑ 3.18% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.2B | ↓ 1.33% |
Net Income | 596.0M | ↓ 11.18% |
Net Profit Margin | 27.71% | ↓ 3.07% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.2B | ↑ 2.88% |
Net Income | 525.0M | ↓ 11.91% |
Net Profit Margin | 23.72% | ↓ 3.99% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.2B | ↓ 1.04% |
Net Income | 599.0M | ↑ 14.1% |
Net Profit Margin | 27.35% | ↑ 3.63% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 10.8B | ↑ 25.52% |
Total Liabilities | 8.6B | ↑ 26.35% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 11.5B | ↑ 7.13% |
Total Liabilities | 8.8B | ↑ 2.85% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 13.6B | ↑ 17.88% |
Total Liabilities | 9.8B | ↑ 11.3% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 13.9B | ↑ 2.14% |
Total Liabilities | 9.4B | ↓ 4.88% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 14.9B | ↑ 7.37% |
Total Liabilities | 10.5B | ↑ 12.46% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 14.3B | ↓ 4.28% |
Total Liabilities | 9.3B | ↓ 11.66% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 14.9B | ↑ 9.15% |
Total Liabilities | 10.5B | ↑ 16.76% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.8B | ↓ 7.85% |
Total Liabilities | 9.3B | ↓ 11.97% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.7B | ↓ 0.04% |
Total Liabilities | 9.1B | ↓ 1.46% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 14.1B | ↑ 2.6% |
Total Liabilities | 9.0B | ↓ 1.05% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 14.3B | ↑ 1.28% |
Total Liabilities | 9.3B | ↑ 2.91% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 14.3B | ↑ 0.43% |
Total Liabilities | 9.3B | ↑ 0.01% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.8B | ↑ 32.99% |
Investing Cash Flow | -2.3B | ↑ 736.67% |
Financing Cash Flow | 533.0M | ↓ 312.35% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.8B | ↑ 0.28% |
Investing Cash Flow | -504.0M | ↓ 77.69% |
Financing Cash Flow | -951.0M | ↓ 278.42% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.1B | ↑ 18.44% |
Investing Cash Flow | -572.0M | ↑ 13.49% |
Financing Cash Flow | 123.0M | ↓ 112.93% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.2B | ↑ 4.09% |
Investing Cash Flow | -458.0M | ↓ 19.93% |
Financing Cash Flow | -1.9B | ↓ 1613.82% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.9B | ↓ 13.6% |
Investing Cash Flow | -883.0M | ↑ 92.79% |
Financing Cash Flow | -904.0M | ↓ 51.45% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 741.0M | ↑ 40.87% |
Investing Cash Flow | -438.0M | ↑ 253.23% |
Financing Cash Flow | 780.0M | ↓ 247.45% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 549.0M | ↓ 25.91% |
Investing Cash Flow | -216.0M | ↓ 50.68% |
Financing Cash Flow | -1.8B | ↓ 331.03% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 183.0M | ↓ 66.67% |
Investing Cash Flow | -80.0M | ↓ 62.96% |
Financing Cash Flow | -494.0M | ↓ 72.59% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 724.0M | ↑ 295.63% |
Investing Cash Flow | -567.0M | ↑ 608.75% |
Financing Cash Flow | -416.0M | ↓ 15.79% |
Sell
Neutral
Buy
Zoetis Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Zoetis Inc. | 5.77% | -5.62% | -5.85% | -9.99% | 57.03% |
Neurocrine Biosciences Inc. | 7.56% | 2.78% | 45.55% | 52.55% | 67.01% |
Haleon Plc Spon Ads | 7.53% | 11.87% | 3.28% | 23.35% | 23.35% |
Viatris Inc. | 12.75% | -1.42% | 12.21% | -15.03% | -28.03% |
Catalent, Inc. | 4.08% | 11.91% | 19.53% | -48.27% | 2.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Zoetis Inc. | 34.62 | 34.62 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
Neurocrine Biosciences Inc. | 39.75 | 39.75 | 0.44 | 3.99 | 0.18 | 0.1 | NA | 23.72 |
Haleon Plc Spon Ads | 29.9 | 29.9 | 1.69 | 0.39 | 0.07 | 0.04 | 0.02 | 1.8 |
Viatris Inc. | 224.4 | NA | 0.06 | 2.73 | 0.0 | 0.03 | 0.04 | 16.81 |
Catalent, Inc. | 211.02 | NA | 2.06 | 0.2 | -0.28 | -0.01 | NA | 19.96 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Zoetis Inc. | Buy | $82.0B | 57.03% | 34.62 | 27.38% |
Neurocrine Biosciences Inc. | Buy | $14.7B | 67.01% | 39.75 | 18.65% |
Haleon Plc Spon Ads | Buy | $41.0B | 23.35% | 29.9 | 9.64% |
Viatris Inc. | Hold | $14.2B | -28.03% | 224.4 | -0.37% |
Catalent, Inc. | Hold | $10.6B | 2.08% | 211.02 | -28.44% |
Insights on Zoetis Inc.
Revenue is down for the last 2 quarters, 2.21B → 2.19B (in $), with an average decrease of 1.0% per quarter
Netprofit is up for the last 2 quarters, 525.0M → 599.0M (in $), with an average increase of 12.4% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 45.5% return, outperforming this stock by 51.4%
In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 62.6%
Vanguard Group Inc
BlackRock Inc
State Street Corporation
State Farm Mutual Automobile Ins Co
Bank of America Corp
Morgan Stanley - Brokerage Accounts
In the quarter ending March,2024. Zoetis Inc. has declared dividend of $0.43
Read MoreZoetis Inc. is an American drug company, the worlds largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the worlds largest drug maker, but with Pfizers spinoff of its 83% interest in the firm it is now a completely independent company.
Organization | Zoetis Inc. |
Employees | 14100 |
CEO | Ms. Kristin C. Peck |
Industry | Health Technology |